Viroblock Raises CHF750K in Final Close of Series C Financing Round

Viroblock S.A., a Switzerland-based anti-viral company, has held a CHF750k second and final closing of its Series C financing round, which initially closed in October 2011 (read here).

This additional investment, from a small group of angel investors, has brought the total amount raised in the round to CHF4m.

The company intends to use the new capital to speed up the production and launch its anti-viral face mask, which is expected to be launched in late 2012 or early 2013.
To this end, the company added Mr. David Frederick, Dr. Winfried Mayer and Dr. Erich Platzer to its Board of Directors. They joined Dr. Peter Pfister and Mr. Gian-Luigi Berini.

Led by CEO Jamie Paterson and Chairman Peter Pfister, Viroblock focuses on developing a novel anti-viral technology that is both rapid acting and broad spectrum. Applied to non-woven fabric, the technology is particularly suitable for air filtration products.



Join the discussion